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Abstract
Background: Concerns have been raised that marginalised populations may not achieve adequate compliance to
antiretroviral therapy. Our objective was to describe the long-term virological, immunological and mortality
outcomes of providing highly active antiretroviral therapy (HAART) with strong adherence support to HIV-infected
female sex workers (FSWs) in Burkina Faso and contrast outcomes with those obtained in a cohort of regular HIV-
infected women.
Methods: Prospective study of FSWs and non-FSWs initiated on HAART between August 2004 and October 2007.
Patients were followed monthly for drug adherence (interview and pill count), and at 6-monthly intervals for
monitoring CD4 counts and HIV-1 plasma viral loads (PVLs) and clinical events.
Results: 95 women, including 47 FSWs, were followed for a median of 32 months (interquartile range [IQR], 20-41).
At HAART initiation, the median CD4 count was 147 cells/μl (IQR, 79-183) and 144 cells/μl (100-197), and the mean
PVLs were 4.94 log10copies/ml (95% confidence interval [CI], 4.70-5.18) and 5.15 log10 copies/ml (4.97-5.33), in FSWs
and non-FSWs, respectively. Four FSWs died during follow-up (mortality rate: 1.7 per 100 person-years) and none
among other women. At 36 months, the median CD4 count increase was 230 cells/μl (IQR, 90-400) in FSWs vs. 284
cells/μl (193-420) in non-FSWs; PVL was undetectable in 81.8% (95% CI, 59.7-94.8) of FSWs vs. 100% (83.9-100) of
non-FSWs; and high adherence to HAART (> 95% pills taken) was reported by 83.3% (95% CI, 67.2-93.6), 92.1%
(95% CI, 78.6-98.3), and 100% (95% CI, 54.1-100) of FSWs at 6, 12, and 36 months after HAART initiation,
respectively, with no statistical difference compared to the pattern observed among non-FSWs.
Conclusions: Clinical and biological benefits of HAART can be maintained over the long term among FSWs in
Africa and could also lead to important public health benefits.
Background
Highly active antiretroviral therapy (HAART) pro-
grammes are now widely available in Africa. High and
sustainable efficacy, similar to that achieved in industria-
lised settings, can be obtained despite frequent treat-
ment initiation at a later stage of HIV disease
progression [1-4]. Beside individual benefits, HAART
also has potential public health benefits [5], through
reduced HIV genital shedding [6] and decreased trans-
mission [7-10], which forms the core hypothesis of the
much debated ‘Treatment as Prevention’ concept [11].
Professional female sex workers (FSWs), alongside less
visible groups involved in part-time transactional sex
such as bar workers, mobile fruit sellers [12], represent
an important core HIV transmitter group that plays a
central role in the dynamics of HIV transmission in
West Africa [13,14]. The estimated population attributa-
ble fraction for prevalent HIV infection related to sexual
contact with FSWs was 84% and 76% in the male adult
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the early 2000’s, respectively [15]. Several HIV preven-
tion intervention programmesh a v et a r g e t e dh i g h - r i s k
populations by providing access to condoms, promoting
behaviour change and offering sexually transmitted
infections (STI) care [16,17], but few programmes have
specifically provided HAART, because of the logistical
difficulty of implementing complex programmes in
these often marginalised and hard-to-reach populations,
with perceived poor social or familial support for drug
adherence. We hypothesised that this group would have
a similar adherence to HAART as non-FSWs, and con-
sequently would have similar treatment outcomes, pro-
vided sufficient support is supplied by health care
services and the community.
The objectives of the research were to measure the
long term virological, immunological and clinical effi-
cacy of HAART in a cohort of FSWs in Burkina Faso
and contrast these treatment outcomes with those
obtained among in a contemporary cohort of non-FSW
HIV-positive women taking HAART.
Methods
Setting and patients
We conducted a prospective observational study nested
within the Yerelon open cohort of high-risk women
(ANRS 1222) described previously [18]. Since 1998, the
Yerelon programme has been offering confidential HIV
prevention and care services to professional and non-
professional FSWs living in Bobo-Dioulasso, Burkina
Faso [12]. Participants were recruited between Decem-
ber 2003 and January 2005 for the first enrolment per-
iod, and between March 2007 and September 2007 for
the second enrolment period. Potential participants were
recruited through a network of peer-educators, then
enrolled if eligible and consenting to study procedures
and followed up at a dedicated clinic located within a
public health facility. All participants benefited from fre-
quent and regular peer-led information and education
sessions on condom use, HIV and STI prevention, and
HIV disease progression. Between August 2004 and Jan-
uary 2005, women from local organizations of people
living with HIV/AIDS (PLWHA) and from the Univer-
sity Hospital in Bobo-Dioulasso were recruited addition-
ally to participate in two trials of Herpes Simplex Virus
(HSV) suppressive therapy [6,19], resulting in both
FSWs and non-FSWs to form the cohort population.
Since April 2004, HAART has been provided to HIV-
infected participants who were or became eligible
according to the WHO guidelines for HIV care [20]. At
that date, 23 women from local PLWHA organizations
and the University Hospital were already on HAART.
The Yerelon Cohort Research Programme has been
approved by the Centre Muraz institutional review
board, and the ethics committees of the Burkina Faso
Ministry of Health and the London School of Hygiene
& Tropical Medicine.
Study procedures
Cohort participants were invited to attend the study
clinic every four months for routine follow-up visits,
including collection of socio-demographic, behavioural,
clinical and biological data. Study participants who
started HAART were followed at closer intervals: weekly
during the first two weeks, and monthly during the
whole follow-up for clinical examination, detection of
drug adverse effects and counselling on adherence. CD4
+ cell count and HIV-1 PVL were measured every six
months. For patients who missed follow-up visits, tele-
p h o n ec a l l sa n dh o m ev i s i t sw e r em a d eb yat e a mo f
peer-educators and social workers. Information on cause
of death was obtained through hospital files and inter-
views of relatives during home visits or telephone calls.
Prevention of opportunistic infections using cotrimoxa-
zole was systematically offered to all patients according
to WHO 2006 guidelines [21].
Antiretroviral therapy
HAART initiation and monitoring followed national
guidelines adapted from WHO [20]. Accordingly,
women with CD4+ count ≤ 200 cells/μl, WHO AIDS
stage IV, or WHO stage III and CD4 count ≤ 350 cells/
μl, were eligible for HAART. The first line treatment
regimen consisted of triple-drug combination including
two nucleoside reverse transcriptase inhibitors (NRTIs)
(zidovudine [AZT] or stavudine [d4T] in case of anae-
mia, and lamivudine [3TC]) with either (i) a non-
nucleoside reverse transcriptase inhibitor (NNRTI), pre-
ferably efavirenz for women infected with HIV-1 or
women infected with both HIV-1 and HIV-2 with effec-
tive contraception, or nevirapine for women not desiring
contraception, or (ii) a protease inhibitor (PI) (indinavir
plus ritonavir or nelfinavir), which was used also for sec-
ond line treatment.
Counselling on HAART adherence and adverse events
was provided by the physician and the drug dispensing
nurse each month. When adherence was not optimal,
clinical psychologists provided additional counselling
and discussed obstacles to adherence. Peer-educators
regularly organised group information and education
sessions on treatment adherence at the study clinic.
Adherence counselling sessions started before HAART
initiation and continued throughout the study period.
The adherence procedures and support measures were
the same for all participants. The need for this multidis-
ciplinary approach to adherence support was identified
through qualitative researchc a r r i e do u ta tt h eo n s e to f
the Yerelon project (unpublished). Attendance to
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was provided to participants.
Biological measurements
HIV seropositivity was determined either with two com-
plementary enzyme-linked immunosorbent assays (ELI-
SAs) [22] or using a rapid testing strategy with
Determine (Abbott), followed by Genie II (BioRad), as
recommended by WHO [23], with an ELISA confirma-
tory testing for discrepant results. CD4+ count was mea-
sured using FACScan (Becton Dickinson, Flatlands, NJ)
and plasma HIV-1 RNA was quantified using a real-
time PCR assay (Generic HIV Viral Load
®,B i o c e n t r i c ,
Bandol, France), with a lower limit of detection of 300
[2.48 log10] copies/ml [24]. HSV-2 serology was per-
formed using a specific IgG2 ELISA (Kalon Biologicals)
with high sensitivity and specificity in African serum
samples [25].
Data on adverse events were obtained from visit forms
and from routine and acute laboratory investigations,
including haemograms, kidney and liver functions.
Laboratory tests were planned at 2, 4, and 16 weeks,
then every 4 months and when clinically indicated. Ser-
ious adverse events were defined based on the ANRS
scaling system [26].
Statistical analysis
Outcomes for HAART efficacy in this study included: (i)
mortality rates; (ii) median values for CD4+ T-cell count
and CD4+ T-cell gain at 6, 12, 24, and 36 months after
HAART initiation; (iii) virological success, defined as
two consecutive samples withu n d e t e c t a b l eH I V - 1P V L
(< 300 copies/ml) after HAART initiation; (iv) primary
virological failure, defined as persistence of detectable
HIV-1 PVL 6 months after HAART initiation; and (v)
secondary virological failure, defined by at least one
plasma sample with detectable HIV-1 RNA, not due to
HAART interruption, after initial virological success.
Participants were considered lost to follow-up if their
last contact with the study team was at least 6 months
prior to the study end, i.e., if no information on vital
status could be recorded between 30 April and 30 Octo-
ber 2007.
Mortality probability was estimated using the Kaplan-
Meier method. Undetectable PVLs were allocated a
value equal to half the detection threshold, and plasma
HIV-1 RNA copies/ml were log10 transformed to nor-
malise their distribution.
HAART adherence was assessed every month by pill
count and expressed as the mean of the proportion of
pills taken to pills that should have been taken, for each
antiretroviral drug during the previous 30 days.
The statistical analysis was conducted using Stata
version 9.0 (Stata Corp, Texas). Univariate
comparisons were performed using the Chi-2 test for
qualitative outcomes and the Student t-test for quanti-
tative outcomes. The log-rank test was used to assess
unadjusted differences between the survival Kaplan-
Meier curves.
Results
Characteristics of participants at HAART initiation
Forty seven FSWs and 48 non-FSWs started antiretro-
viral treatment and were followed up between August
2004 and October 2007 (Figure 1). Characteristics of
the 95 participants at HAART initiation are detailed in
Table 1. All women were infected with HIV-1, and one
patient was infected with HIV-1 and HIV-2. The med-
ian age was 33 years (interquartile range [IQR], 28-39).
Among FSWs, the median number of years of transac-
tional sex was 8 (IQR, 5-13) and the median number
of clients per week was 2 (IQR, 0-2). Twice as many
FSWs than non-FSWs admitted recent alcohol con-
sumption (64% vs. 33%, P = 0.003). At HAART initia-
tion, the median CD4+ count was 147 cells/μl( I Q R ,
79-183) and 144 (100-197) in FSWs and non-FSWs,
respectively, and the mean PVLs were 4.94 log10
copies/ml (95% confidence interval [CI], 4.70-5.18) and
5.15 (4.97-5.33), respectively (P = 0.16). 70% of FSWs
and 69% of non-FSWs were at WHO clinical stages
III/IV.
Antiretroviral treatment and side effects
The HAART regimen consisted of two NRTIs plus one
NNRTI in 92 (97%) patients, and two NRTIs plus one
PI in 3 (3%) patients (Table 1). During follow-up, six
(6%) women experienced a serious adverse event: one
woman had to be switched from efavirenz to nevirapine
because of central neurological disturbances, one
woman stopped d4T and switched to AZT because of
peripheral neuropathy, and four women were switched
from AZT to d4T because of severe anaemia. Moreover,
17 (18%) women were switched from efavirenz to nevir-
apine: 14 who became pregnant, and 3 who wanted to
become pregnant.
Adherence
The median follow-up of all participants was 32 months
(IQR, 20-41 months), yielding 233 person-years of
observation. The proportion of FSWs with ≥ 95% adher-
ence to their antiretroviral regimen by pill count was
83.3% (95% CI, 67.2-93.6), 92.1% (95% CI, 78.6-98.3),
and 100% (95% CI, 54.1-100) 6, 12, and 36 months after
HAART initiation, respectively. These values were not
statistically different from the corresponding proportions
for non-FSWs which were 95.3% (95% CI, 84.2-99.4, P =
0.08), 92.7% (95% CI, 80.1-98.5), and 100% (95% CI,
63.1-100).
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Seven women (including two FSWs) were lost during
follow-up and four FSWs died (mortality rate: 1.7 per
100 person-years) versus none in the non-FSW group.
Among FSWs, the cumulative probability of death after
HAART initiation was 0.06 (95% CI, 0.02-0.18) at 12
months and 0.09 (95% CI, 0.03-0.22) at 36 months,
respectively, which was significantly different from mor-
tality rates observed in non-FSWs (logrank test = 0.04,
Figure 2). The median time between HAART initiation
118 women on HAART 
followed up in the cohort 
95 women started HAART  
during follow-up in the cohort 
23 started HAART 
before enrollment in the cohort 
47 FSWs 
111 person-years of follow-up 
48 non FSWs 
122 person-years of follow-up 
6 had some data censored 
2 dropped out 
4 died 
5 had some data censored 
5 dropped out 
0 died 
47 FSWs  
Included in analysis 
48 non FSWs 
Included in analysis 
Figure 1 Flowchart of enrollment and follow-up of FSWs and non-FSWs receiving HAART in Bobo-Dioulasso, Burkina Faso, 2004-2007.
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Page 4 of 10and death was 3.4 months (IQR, 2.3-10.7 months). The
median CD4+ count at HAART initiation was 118 cells/
μl (IQR, 85-195) and 146 cells/μl (IQR, 93-191) in
women who died versus women who survived, respec-
tively (P = 0.95). Among the deceased women, two
already had AIDS-defining symptoms at HAART initia-
tion visit. Presumptive causes of death were tuberculosis
for one woman and wasting syndrome for another,
whilst no cause of death could be ascertained for two
women in whom no severe event had been recorded in
the 6 months prior to death.
Biological outcomes
The median change in CD4+ count and the percentage
of patients with undetectable HIV-1 PVL are presented
in Figures 3 and 4. Among FSWs, the median values for
CD4+ count reached 234 cells/μl (IQR, 180-327) 6
months after HAART initiation, 306 cells/μl( I Q R ,2 4 9 -
382) after 12 months, and 343 cells/μl (IQR, 230-553)
after 36 months. The median cumulative increases in
the CD4+ count were 132 cells/μl (IQR, 41-196), 177
cells/μl (IQR, 105-255), and 230 cells/μl (IQR, 90-400),
at 6, 12, and 36 months, respectively (Figure 3). These
Table 1 Characteristics of female sex workers (FSWs) and non-FSWs at their HAART initiation visit in Bobo-Dioulasso,
Burkina Faso, 2004-2007
Characteristics FSWs
(N = 47)
Non-FSWs
(N = 48)
P-value
n (%) n (%)
Socio-demographic characteristics
Age, median (IQR), years 31 (27, 35) 35 (31, 41) 0.01
Education (n = 89) 0.86
Secondary 10 (22) 11 (26)
Primary 15 (32) 12 (28)
Illiterate 21 (46) 20 (46)
Age at first sex, median (IQR), years (n = 89) 16 (15, 17) 16 (15, 18) 0.98
Married (n = 89) 10 (22) 10 (23) 0.86
Trip outside the city last 12 months (n = 89) 24 (52) 20 (47) 0.59
Behavioural characteristics
Alcohol use in the last week 30 (64) 16 (33) 0.003
Has a steady sexual partner at enrolment (n = 88) 37 (80) 21 (50) 0.003
No. sexual intercourses in the last week, median (IQR), (n = 88) 2 (0-3) 0 (0-1) < 0.001
Always uses condoms with unknown casual sexual partners (n = 88) 35 (76) 31 (74) 0.81
Always uses condoms with known sexual partners (n = 88) 25 (54) 30 (71) 0.10
Always uses condoms with steady sexual partner(s) (n = 31) 3 (13) 3 (38) 0.16
Clinical and biological characteristics
Body mass index, median (IQR), kg/m
2 20.7 (18.4, 23.6) 19.0 (17.4, 21.8) 0.08
WHO clinical stages (n = 88)* 0.94
Stage I 4 (8) 4 (9)
Stage II 10 (22) 9 (22)
Stage III 27 (59) 22 (52)
Stage IV 5 (11) 7 (17)
CD4+ count, median (IQR), cells/μL (n = 95) 147 (79, 183) 144 (100, 197) 0.12
Plasma HIV-1 RNA, mean (95% CI), log10 copies/ml (n = 92) 4.94 (4.70, 5.18) 5.15 (4.97, 5.33) 0.16
HSV-2 seropositive 44 (94) 46 (96) 0.68
HAART regimen 0.11
AZT/3TC/efavirenz 29 (62) 24 (50)
d4T/3TC/nevirapine 10 (22) 12 (25)
d4T/3TC/efavirenz 3 (6) 10 (21)
AZT/3TC/nevirapine 3 (6) 1 (2)
AZT/3TC/nelfinavir 2 (4) 0 (0)
AZT/3TC/indinavir-ritonavir 0 (0) 1 (2)
NOTE: Data are the no. (%) of women, unless otherwise indicated.
AZT, zidovudine; d4T, stavudine; 3TC, lamivudine; HAART, highly active antiretroviral therapy; IQR, interquartile range.
*5 missing values and in 2 patients, WHO clinical stage could not be determined at HAART initiation because of missing data such as weight loss or prior
opportunistic diseases.
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from those observed in non-FSWs.
Dynamics of PVL over time after HAART initiation
was not statistically different between FSWs and non-
FSWs beyond the first 6-month period on HAART
(Figure 4). However, over the whole follow-up period,
the rate of virological success was 76.7% (95% CI, 61.4-
88.2) among FSWs and 95.5% (95% CI, 84.5-99.4)
among non-FSWs (P = 0.01). The rate of primary viro-
logical failure at 6 months was 20.6% (95% CI, 8.7-
37.9) among FSWs and 2.8% (95% CI, 0.1-14.5) among
non-FSWs (P = 0.03). Secondary virological failures
occurred in three women (5.3%, 95%CI, 1.1-14.6),
including two FSWs.
Discussion
We describe the long-term mortality and efficacy of
HAART in one of the rare longitudinal studies of female
sex workers in sub-Saharan Africa. To our knowledge,
this is the first report showing that clinical and biologi-
cal efficacy of HAART can be maintained in the long
term in a hard-to-reach, mobile and highly stigmatised
population in sub-Saharan Africa.
Follow-up rates were very high in this cohort, includ-
ing during the first year of treatment, in contrast with a
pooled analysis of 5491 adult patients starting HAART
in 15 treatment programmes in Africa, Asia and South
America [27], in which the scaling-up of HAART pro-
grammes was associated with a higher probability of loss
to follow-up. This may be explained by the fact that our
study was carried out in a clinical research centre, with
provision of free care, low numbers of patients, intensive
counselling and active tracing of patients, which cannot
be representative of all low-resource clinical settings.
Overall, mortality was remarkably low in this study, in
contrast with other studies carried out in low-income
countries [28-30]. Mortality was higher during the first
3 months following HAART initiation, as reported in
similar settings, albeit at even higher levels [28,31-34].
Despite relatively low CD4+ counts at HAART initia-
tion, the long term virological, immunological and clini-
cal responses to HAART among FSWs were broadly
comparable to previous reports obtained in general
population cohorts of HIV-infected individuals in indus-
trialized countries [35] and in sub-Saharan African set-
tings with relatively low patients numbers and intensive
Figure 2 Kaplan-Meier curves of cumulative mortality probability among FSWs and non-FSWs receiving HAART in Bobo-Dioulasso,
Burkina Faso, 2004-2007.
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cohort, FSWs had an apparently less favourable virologi-
cal response to HAART than non-FSWs. This can not
readily be explained by more advanced disease at base-
line, higher HIV-1 plasma viral loads, or different HSV-
2 seroprevalence - an infection known to potentially
enhance HIV-1 replication and disease progression [37].
A higher rate of HIV-1 super-infection among sex work-
ers [38] or higher levels of acquired HIV-1 resistant
strains, as indicated by the higher rates of primary viro-
logical failure observed in FSWs may be possible expla-
nations which would warrant further investigations.
Despite similar levels of support, the lower adherence in
FSWs, although not statistically significant, but perhaps
compounded by higher alcohol use, may also explain
the trend for higher rate of primary virological failures
in this group.
Our study shows, however, that high levels of adher-
ence to HAART can be achieved and maintained
beyond the initial period of clinical benefits among
FSWs, even if some reporting bias may have occurred.
Strong support measures that included close follow-up
with an outreach team and a peer-educator-based orga-
nization, a specific adherence support provided by peer-
educators, physicians, nurses and psychologists on a
monthly basis were certainly central to this achievement.
Because FSWs often experience broken down familial
and social relationships, we strongly advocate for a spe-
cific multidisciplinary approach to adherence support.
We also believe that building trustful, respectful and
non-judgmental relationships between FSWs and health
care workers is crucial. For example, we tried to
decrease stigma and discrimination by following FSWs
and non-FSWs together at the same clinic.
In this West African setting, HAART regimens con-
taining mainly zidovudine (or stavudine), lamivudine
and efavirenz demonstrated good safety and tolerance.
The reported adverse events were within the range, both
for type and frequency, of those previously reported in
similar settings [2,39]. Our data confirm the good safety
Months of treatment  M6  M12  M18  M24  M30  M36 
FSWs ( )             
Expected visits, No.  44  44  38  31  26  23 
CD4 measurement available, No.  43  41  35  29  26  22 
Non-FSWs ( )             
Expected visits, No.  48  47  42  32  30  25 
CD4 measurement available, No.  48  46  39  30  28  24 
P value for difference between 
values at each timepoint  0.18  0 .40  0.11  0.17  0.57  0.30 
Figure 3 Median increases in the CD4+ cell count from baseline (vertical bars represent interquartile ranges) in FSWs and non-FSWs
receiving HAART, over time.
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and high risk of anemia.
Our study had a number of limitations. First, our sam-
ple size was small, and whilst it allowed for reasonably
precise estimates of outcomes, it may not have allowed
for identification of small differences in HAART
response between the FSW and non-FSW groups. Sec-
ond, this FSW population cannot be taken to be repre-
sentative of other FSW populations. Clearly, their risk
behaviour at the time of HAART initiation was mark-
e d l yd i f f e r e n tf r o mt h a ta tt i m eo fc o h o r te n r o l m e n t
[12]. This may be attributed to any combination of (i)
the effect of other behavioural interventions provided by
the study team, (ii) a modification of behaviour as
women perhaps became sicker, (iii) answers motivated
by strong social desirability, and (iv) the bias inherent to
any long term cohort studies, whereby participants are
progressively selected towards more compliant and
lower risk individuals. Third, some HIV-1 PVL measure-
ments were missing during the period of 24 and 30
months after HAART initiation, though not after 36
months. This is a result of both logistical difficulties to
obtain PVL at one period of the survey, and of our
study design, as women recruited late in the cohort did
not have any follow-up beyond 24-30 months. Fourth,
we could not perform HIV resistance testing. While we
might anticipate a low rate of emergence of resistant
strains given the good virological responses, it will be
important to monitor both primary and secondary resis-
tance to antiretrovirals because of the public health
Months of treatment  M6  M12  M18  M24  M30  M36 
FSWs ( )             
Expected visits, No.  44  44  38  31  26  23 
HIV-1 RNA measurement available, No.  34  35  30  8  12  22 
Non-FSWs ( )             
Expected visits, No.  48  47  42  32  30  25 
HIV-1 RNA measurement available, No.  36  43  34  4  13  21 
P value for difference between values at 
each timepoint  0.03  0.06  0.29  1.00  0.10  0.11 
Figure 4 Proportion of FSWs and non-FSWs receiving HAART with undetectable plasma HIV-1 RNA (< 300 copies/ml) (vertical bars
represent 95% confidence intervals), over time. (*: HIV-1 RNA measurement was not systematically available because of logistical constraints
during the period months 24 to 30).
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from a core group [40,41]. It appears also important to
determine the cause of primary virological failures in
this group of highly exposed women. Finally, our results
may not be generalizable to populations with fewer
resources and less intense follow-up and counselling
such as would be typical during scaled-up programmes.
The potential impact of HAART on HIV-1 sexual
transmission was not determined directly during this
study, but it is important to consider in core groups.
Future modelling studies should include data from set-
tings where core groups have much higher HIV preva-
lence than the general population and thus may play a
key role in HIV transmission dynamics, and data from
the effect of HAART on sexual behaviour in these
groups.
Conclusions
HAART becomes an increasingly attractive health
investment even in settings with limited resources [42].
We have shown that introducing HAART into hard-to-
reach and marginalised populations was feasible and
that the clinical and biological benefits could be main-
tained over long periods, which could lead to important
public health benefits.
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